News & Press

2018

• January 2018 – Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer

2017

• September 2017 – Hereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month
• May 2017 – Medicare Coverage of Prolaris^® Test Expands with the Addition of Men Diagnosed with Favorable Intermediate Risk Prostate Cancer
• May 2017 – Myriad Genetics’ Prolaris^® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer
• May 2017 – Myriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting
• February 2017 – Myriad’s Prolaris^® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer

2016

• May 2016 – Myriad to Present Three New Studies at the AUA Annual Meeting
• January 2016 – Myriad Advances Prostate and Renal Cancer Molecular Diagnostic Tests at the 2016 ASCO Genitourinary Cancers Symposium

2015

• October 2015 – Myriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris(R) for Members With Localized Prostate Cancer
• May 2015 – Myriad Validates Active Surveillance Threshold With Prolaris(R) for Men With Prostate Cancer
• May 2015 – Myriad to Present New Clinical Data on Prolaris(R) at the AUA 2015 Annual Meeting
• March 2015 – Myriad Announces Prolaris^®Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting

2014

• December 2014 –Study Shows Prolaris(R) Could Save Healthcare System $6 Billion Over 10 Years

• October 2014 – Myriad Announces Inclusion of Prolaris^® Test in NCCN Guidelines
• October 2014 – Myriad Receives Draft Medicare Coverage for Prolaris®
• February 2014 – Myriad Genetics Publishes Prolaris^® Data in the Journal of Urology
• January 29, 2014 – Myriad’s Prolaris Test Significantly Modifies Treatment Decisions for Patients With Prostate Cancer
• January 23, 2014 – Myriad Genetics to Present Five Clinical Studies at 2014 ASCO GU Cancer Symposium

2013

• December 2013 – Myriad’s Prolaris^® Test Guides Treatment Decisions for Men with Prostate Cancer
• May 2013 – Myriad to Present New Molecular Data for Patients With Prostate Cancer at the American Urological Association 2013 Annual Meeting: Prolaris® Signature Predicts Recurrence and Mortality
• March 2013 – Myriad’s Prolaris Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study

2012

• November 2012 – Myriad Genetics’ Prolaris Test Predicts Biochemical Recurrence in Prostate Cancer Patients Following Radiation Therapy
• February 27, 2012 – Prolaris Test Awarded Best Poster Honor at 27th Annual EAU Congress in Paris, France
• February 2, 2012 – Myriad’s Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy

2011

• June 2011 – Myriad’s Prolaris Test Shown to Significantly Predict Prostate Cancer Outcome From Needle Biopsy Tissue
• May 2011 – Myriad Genetics Announces Presentation of Prostate Cancer Study at American Society for Clinical Oncology Annual Meeting
• March 2011 – Myriad Genetics Launches Prolaris: First Diagnostic Test to Predict Prostate Cancer Recurrence
• February 2011 – Myriad’s Prolaris Test Shown to Significantly Predict Prostate Cancer Outcome

2010

• October 14, 2010 – Myriad Genetics to Present Prostate Cancer Data at the ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer
• October 11, 2010 – Myriad Genetics’ Prolaris Test Accurately Predicts Survival with Prostate Cancer
• March 2010 – Novel Gene Expression Test, Prolaris, Accurately Predicts Prostate Cancer Recurrence